Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223258 | 1.00 | TP53 (0.47) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL18496413 | 0.97 | TP53 (0.45) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL6068367 | 0.91 | TP53 (0.43) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL14998053 | 0.88 | ALDH1A1 (0.55) | TP53KMT2AALDH1A1KDM4EP2RY14 | |
| SCHEMBL29831851 | 0.88 | CYP1A2 (0.54) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL15964665 | 0.88 | CYP1A2 (0.54) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL15075362 | 0.87 | TP53 (0.48) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL2921176 | 0.87 | SMN1; SMN2 (0.52) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL30121985 | 0.87 | TP53 (0.48) | TP53KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL17611623 | 0.86 | TP53 (0.50) | TP53KMT2AALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017025981-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-16 | — | — | WO | claimed |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| EP-4165028-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | Adverio Pharma GmbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| CN-115947689-A | Method for synthesizing riociguat intermediate by continuous flow microreactor | 湖南华腾制药有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115697978-A | Method for preparing methyl {4,6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate | 阿德弗里奥药品有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-107406422-B | Pyrazole derivatives as sGC stimulators | 赛科理音医疗有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2021254981-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-6903089-B1 | Lactam-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| US-6833364-B1 | Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine | BAYER HEALTHCARE AG (DE) | 2004-12-21 | — | — | US | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6693102-B2 | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-17 | — | — | US | disclosed |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224945-A1 | Novel substituted pyrazole derivatives | CYP11B2, CYP11B1, ADRB3 | TP53 4342/4885KMT2A 4581/4885ALDH1A1 230/4885 |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | POLL, F9, DNMT3B | TP53 3873/4885KMT2A 875/4885ALDH1A1 3761/4885 |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | POLL, DNMT3B, MTAP | TP53 3449/4885KMT2A 453/4885ALDH1A1 3851/4885 |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | GUCY1A1, GUCY1A2, GUCY1B1 | TP53 3993/4885KMT2A 4310/4885ALDH1A1 712/4885 |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | GPR3, NOS3, NPR3 | TP53 4547/4885KMT2A 3894/4885ALDH1A1 2339/4885 |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | NOS3, PDE3A, GPR3 | TP53 4431/4885KMT2A 4314/4885ALDH1A1 1768/4885 |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | GUCY1A2, GUCY1A1, GUCY1B2 | TP53 4151/4885KMT2A 3714/4885ALDH1A1 1989/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | TP53 3665/4885KMT2A 4306/4885ALDH1A1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.